<DOC>
	<DOCNO>NCT01474239</DOCNO>
	<brief_summary>This randomize , non-comparative study evaluate efficacy safety Avastin ( bevacizumab ) patient recurrent glioblastoma . Patients randomize receive Avastin 10 mg/kg intravenously every 2 week fotemustine 75 mg/m2 day 1 , 8 15 , follow , 5 week interval , 100 mg/m2 intravenously every 3 week . Treatment fotemustine serf calibration arm formal efficacy comparison make two treatment arm . The anticipated time study treatment disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) And Fotemustine Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fotemustine</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Diagnosis recurrent glioblastoma multiforme ( Grade IV ) Previous treatment temozolomide radiotherapy First recurrence standard adjuvant treatment ( surgery , follow radiotherapy chemotherapy ) Adequate hematological , biochemical organ function Previous treatment Avastin antiangiogenic drug Residual relevant toxicity result previous therapy Radiotherapy within 3 month prior diagnosis disease progression Chemotherapy previous 4 week Other active inactive malignancy ( except carcinoma situ cervix , prostate basal cell carcinoma ) Clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>